Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets in Healthy Chinese Participants

被引:3
作者
Cong, Duanduan [1 ]
Qi, Wenyuan [1 ]
Liu, Xiaohui [1 ]
Xu, Xiaoyu [1 ]
Dong, Lingyun [2 ]
Xue, Wei [1 ,3 ]
Li, Kexin [1 ,3 ]
机构
[1] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Clin Trial Ctr,Natl Ctr Gerontol,Beijing Key Lab D, Beijing, Peoples R China
[2] Beijing Yeedozencom Healthcare Sci & Technol Co Lt, Beijing, Peoples R China
[3] Beijing Hosp, Clin Trial Ctr, North Bldg B4,1 Dahua Rd, Beijing 100730, Peoples R China
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2023年 / 17卷
关键词
acetylsalicylic acid; salicylic acid; enteric -coated sustained -release; pharmacokinetics; RESISTANCE;
D O I
10.2147/DDDT.S409524
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Purpose: To study and compare the pharmacokinetic characteristics of enteric-coated sustained-release (EcSr) aspirin tablets with enteric-coated (Ec) aspirin tablets (Bayer S.p.A) in healthy Chinese participants.Patients and Methods: In this open, randomized, single-dose, three-way, crossover study, 18 healthy participants randomly received 100 mg EcSr tablets pre-prandially (a.c.), EcSr tablets post-prandially (p.c.), or Ec tablets a.c. in each period. The concentrations of acetylsalicylic acid (ASA) and salicylic acid (SA) in plasma were determined by the LC-MS/MS method, and the pharmacokinetic parameters were calculated using WinNonlin (version 8.1).Results: The essential PK parameters under the three treatment conditions (ie Ec a.c., EcSr a.c. and EcSr p.c.) were as follows: Cmax, ASA: 758.38 & PLUSMN;455.34, 222.77 & PLUSMN;98.04 and 194.54 & PLUSMN;61.19 ng, Tmax, ASA: 6.75(2,16), 4.5(2,11) and 8.25(5,11) h, T1/2, ASA: 0.43 & PLUSMN;0.08, 1.44 & PLUSMN;0.59 and 4.32 & PLUSMN;10.04 h, AUC0-t, ASA: 1008.88 & PLUSMN;452.27, 918.04 & PLUSMN;238.40 and 845.55 & PLUSMN;183.25 h & BULL;ng/mL; Cmax, SA: 6409.38 & PLUSMN;2098.52, 2863.53 & PLUSMN;679.73 and 2913.75 & PLUSMN;853.27ng/mL, Tmax, SA: 7.25(2,24), 10(3.5-14) and 10(7,14) h, T1/2, SA: 2.21 & PLUSMN;0.46, 2.69 & PLUSMN;0.72 and 3.51 & PLUSMN;2.06h, AUC0-t, SA: 29,131.41 & PLUSMN;9376.23, 27,243.97 & PLUSMN;7465.16, 27,240.25 & PLUSMN;7444.67 h & BULL;ng/mL. When taking EcSr aspirin tablets, the 90% confidence intervals of the geometric mean ratios (pre-prandial/post-prandial) of AUC0-t, ASA and AUC0-& INFIN;, ASA, Cmax, SA, AUC0-t, SA and AUC0-& INFIN;, SA were within the range of 80.00%-125.00%.Conclusion: EcSr aspirin tablets showed less inter-individual variation in release and absorption than Ec aspirin tablets, which was well reflected by comparing essential PK parameters. Furthermore, meals had no significant effect on the pharmacokinetics of EcSr aspirin tablets.
引用
收藏
页码:2421 / 2429
页数:9
相关论文
共 10 条
  • [1] The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
    Altman R.
    Luciardi H.L.
    Muntaner J.
    Herrera R.N.
    [J]. Thrombosis Journal, 2 (1)
  • [2] Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus
    Bhatt, Deepak L.
    Grosser, Tilo
    Dong, Jing-fei
    Logan, Douglas
    Jeske, Walter
    Angiolillo, Dominick J.
    Frelinger, Andrew L., III
    Lei, Lanyu
    Liang, Juan
    Moore, Jason E.
    Cryer, Byron
    Marathi, Upendra
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (06) : 603 - 612
  • [3] In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method
    Cas, Michele Dei
    Rizzo, Jessica
    Scavone, Mariangela
    Femia, Eti
    Podda, Gian Marco
    Bossi, Elena
    Bignotto, Monica
    Caberlon, Sabrina
    Cattaneo, Marco
    Paroni, Rita
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [4] [陈夏欢 Chen Xiahuan], 2018, [中国循环杂志, Chinese Circulation Journal], V33, P457
  • [5] Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives
    Christiansen, Mikael
    Grove, Erik Lerkevang
    Hvas, Anne-Mette
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2021, 47 (07) : 800 - 814
  • [6] Aspirin Use to Prevent Cardiovascular Disease US Preventive Services Task Force Recommendation Statement
    Davidson, Karina W.
    Barry, Michael J.
    Mangione, Carol M.
    Cabana, Michael
    Chelmow, David
    Coker, Tumaini Rucker
    Davis, Esa M.
    Donahue, Katrina E.
    Jaen, Carlos Roberto
    Krist, Alex H.
    Kubik, Martha
    Li, Li
    Ogedegbe, Gbenga
    Pbert, Lori
    Ruiz, John M.
    Stevermer, James
    Tseng, Chien-Wen
    Wong, John B.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (16): : 1577 - 1584
  • [8] Drug Resistance and Pseudoresistance An Unintended Consequence of Enteric Coating Aspirin
    Grosser, Tilo
    Fries, Susanne
    Lawson, John A.
    Kapoor, Shiv C.
    Grant, Gregory R.
    FitzGerald, Garret A.
    [J]. CIRCULATION, 2013, 127 (03) : 377 - 385
  • [9] Kedir Hanan Muzeyin, 2021, Int J Gen Med, V14, P4757, DOI 10.2147/IJGM.S326929
  • [10] Pharmaceuticals and Medical Devices Agency PMDA, 2022, PHARM INT FORM BAYAS